Targeting HIF-2 Alpha as a Novel Therapeutic Strategy

This segment provides a detailed introduction to the LITESPARK-011 trial, including its patient population and eligibility criteria. The study enrolled patients with advanced clear cell RCC who had progressed on or after PD-(L)1–based therapy, either in the metastatic or adjuvant setting, and allowed up to two prior lines of systemic treatment. Prior exposure to VEGF TKIs was permitted but not required. Importantly, patients who had previously received lenvatinib or cabozantinib were excluded, reflecting the use of these agents as study treatments. The discussion highlights how these criteria shape the study population and influence the interpretation of results. The speakers note that patients treated with common frontline combinations containing these agents would not have been eligible, which has implications for real-world applicability. This segment emphasizes the importance of understanding trial eligibility when evaluating how study findings may translate into clinical practice.